Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus

Ye,Tai‑Sheng; Zhang,Ying‑Wen; Zhang,Xian‑Mei

doi:10.3892/etm.2016.3218

Protective effects of Danggui Buxue Tang on renal function, renal glomerular mesangium and heparanase expression in rats with streptozotocin-induced diabetes mellitus

Authors:
- Tai‑Sheng Ye
- Ying‑Wen Zhang
- Xian‑Mei Zhang
View Affiliations

Affiliations: Department of Integrated Traditional Chinese and Western Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Integrated Traditional Chinese and Western Medicine, The Third Hospital of Wuhan, Wuhan, Hubei 430060, P.R. China
Published online on: April 1, 2016 https://doi.org/10.3892/etm.2016.3218
Pages: 2477-2483

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Danggui Buxue Tang (DBT) is a simple combination of Radix Astragali and Radix Angelica sinensis (5:1), with a variety pharmacological activities. In the present study, a single intravenous injection of 30 mg/kg streptozotocin and subsequent six weeks of high glucose diet in Sprague Dawley rats were used to induce diabetic nephropathy. Rats with diabetes mellitus showed increased levels of fasting blood glucose (FBG), blood urea nitrogen (BUN), serum creatinine (Scr), serum and urine β2‑microglobulins (β2‑MG), and type IV collagen (all P<0.05). DBT treatment significantly decreased the levels of FBG, BUN, Scr, serum and urine β2‑MG, and type IV collagen. Furthermore, DBT treatment significantly and dose‑dependently restored the ultrastructural injury, and reduced the expression of heparanase, compared with the vehicle (P<0.05). Therefore, DBT may be a novel therapeutic approach for the prevention and treatment of diabetic nephrology.

View Figures

View References

1	Heerspink HJ and de Zeeuw D: The kidney in type 2 diabetes therapy. Rev Diabet Stud. 8:392–402. 2011. View Article : Google Scholar : PubMed/NCBI
2	Abuissa H and O'Keefe J Jr: The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. Diabetes Obes Metab. 10:1157–1166. 2008.PubMed/NCBI
3	Zhang WL, Zheng KY, Zhu KY, Zhan JY, Bi CW, Chen JP, Dong TT, Choi RC, Lau DT and Tsim KW: Chemical and biological assessment of angelica roots from different cultivated regions in a chinese herbal decoction danggui buxue tang. Evid Based Complement Alternat Med. 2013:4832862013. View Article : Google Scholar : PubMed/NCBI
4	Wu YC and Hsieh CL: Pharmacological effects of Radix Angelica sinensis (Danggui) on cerebral infarction. Chin Med. 6:322011. View Article : Google Scholar : PubMed/NCBI
5	Wang Z, Wang J and Chan P: Treating type 2 diabetes mellitus with traditional chinese and Indian medicinal herbs. Evid Based Complement Alternat Med. 2013:3435942013.PubMed/NCBI
6	Toda S, Yase Y and Shirataki Y: Inhibitory effects of astragali radix, crude drug in Oriental medicines on lipid peroxidation and protein oxidative modification of mouse brain homogenate by copper. Phytother Res. 14:294–296. 2000. View Article : Google Scholar : PubMed/NCBI
7	Gao QT, Choi RC, Cheung AW, Zhu JT, Li J, Chu GK, Duan R, Cheung JK, Jiang ZY, Dong XB, et al: Danggui buxue tang - a Chinese herbal decoction activates the phosphorylations of extracellular signal-regulated kinase and estrogen receptor alpha in cultured MCF-7 cells. FEBS Lett. 581:233–240. 2007. View Article : Google Scholar : PubMed/NCBI
8	Zhang YW, Xie D, Xia B, Zhen RT, Liu IM and Cheng JT: Suppression of transforming growth factor-beta1 gene expression by Danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin-induced diabetic rats. Horm Metab Res. 38:82–88. 2006. View Article : Google Scholar : PubMed/NCBI
9	Zhang YW, Xie D, Chen YX, Zhang HY and Xia ZX: Protective effect of Gui Qi mixture on the progression of diabetic nephropathy in rats. Exp Clin Endocrinol Diabetes. 114:563–568. 2006. View Article : Google Scholar : PubMed/NCBI
10	Ha TS: Roles of adaptor proteins in podocyte biology. World J Nephrol. 2:1–10. 2013. View Article : Google Scholar : PubMed/NCBI
11	Chiang YY, Takebayashi S and Oberley TD: In vitro analysis of extracellular matrix production by porcine glomerular mesangial and vascular smooth muscle cells. Am J Pathol. 138:1349–1358. 1991.PubMed/NCBI
12	Lan T, Liu W, Xie X, Xu S, Huang K, Peng J, Shen X, Liu P, Wang L, Xia P and Huang H: Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol Endocrinol. 25:2094–2105. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ke HL, Zhang YW, Zhou BF and Zhen RT: Effects of Danggui Buxue Tang, a traditional Chinese herbal decoction, on high glucose-induced proliferation and expression of extracellular matrix proteins in glomerular mesangial cells. Nat Prod Res. 26:1022–1026. 2012. View Article : Google Scholar : PubMed/NCBI
14	Bame KJ: Heparanases: endoglycosidases that degrade heparan sulfate proteoglycans. Glycobiology. 11:91R–98R. 2011. View Article : Google Scholar
15	Jiang P, Kumar A, Parrillo JE, Dempsey LA, Platt JL, Prinz RA and Xu X: Cloning and characterization of the human heparanase-1 (HPR1) gene promoter: Role of GA-binding protein and Sp1 in regulating HPR1 basal promoter activity. J Biol Chem. 277:8989–8998. 2002. View Article : Google Scholar : PubMed/NCBI
16	Gil N, Goldberg R, Neuman T, Garsen M, Zcharia E, Rubinstein AM, van Kuppevelt T, Meirovitz A, Pisano C, Li JP, et al: Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes. 61:208–216. 2012. View Article : Google Scholar : PubMed/NCBI
17	Zhang YW, Wu CY and Cheng JT: Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-kappaB and IkappaB in renal cortex of streptozotoxin-induced diabetic rats. J Ethnopharmacol. 114:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
18	Clark JD, Gebhart GF, Gonder JC, Keeling ME and Kohn DF: Special report: Guide for the care and use of laboratory animals. ILAR J. 1997:41–48. 1997. View Article : Google Scholar
19	Nakamura T, Terajima T, Ogata T, Ueno K, Hashimoto N, Ono K and Yano S: Establishment and pathophysiological characterization of type 2 diabetic mouse model produced by streptozotocin and nicotinamide. Biol Pharm Bull. 29:1167–1174. 2006. View Article : Google Scholar : PubMed/NCBI
20	Schernthaner G, Grimaldi A, Di Mario U, Drzewoski J, Kempler P, Kvapil M, Novials A, Rottiers R, Rutten GE and Shaw KM: GUIDE study: Double-blind comparison of once-daily gliclazide MR andglimepiride in type 2 diabetic patients. Eur J Clin Invest. 34:535–542. 2004. View Article : Google Scholar : PubMed/NCBI
21	U.S. Food and Drug Administration: Guidance for Industry and Reviewers: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. December;2002.
22	Wang GG, Lu XH, Li W, Zhao X and Zhang C: Protective effects of luteolin on diabetic nephropathy in STZ-induced diabetic rats. Evid Based Complement Alternat Med. 2011:3231712011. View Article : Google Scholar : PubMed/NCBI
23	King AJ: The use of animal models in diabetes research. Br J Pharmacol. 166:877–894. 2012. View Article : Google Scholar : PubMed/NCBI
24	Like AA and Rossini AA: Streptozotocin-induced pancreatic insulitis: New model of diabetes mellitus. Science. 193:415–417. 1976. View Article : Google Scholar : PubMed/NCBI
25	Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S and Danesh FR: Diabetic nephropathy: Mechanisms of renal disease progression. Exp Biol Med (Maywood). 233:4–11. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wolf G: New insights into the pathophysiology of diabetic nephropathy: From haemodynamics to molecular pathology. Eur J Clin Invest. 34:785–796. 2004. View Article : Google Scholar : PubMed/NCBI
27	Dronavalli S, Duka I and Bakris GL: The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 4:444–452. 2008. View Article : Google Scholar : PubMed/NCBI
28	Yeh CH, Chang CK, Cheng KC, Li YX, Zhang YW and Cheng JT: Role of bone morphogenetic proteins-7 (BMP-7) in the renal improvement effect of DangGui (Angelica sinensis) in type-1 diabetic rats. Evid Based Complement Alternat Med. 2011:7967232011. View Article : Google Scholar : PubMed/NCBI
29	Giacco F and Brownlee M: Oxidative stress and diabetic complications. Circ Res. 107:1058–1070. 2010. View Article : Google Scholar : PubMed/NCBI
30	Zhong Y, Deng Y, Chen Y, Chuang PY and Cijiang He J: Therapeutic use of traditional Chinese herbal medications for chronic kidney diseases. Kidney Int. 84:1108–1118. 2013. View Article : Google Scholar : PubMed/NCBI
31	Zhang J, Xie X, Li C and Fu P: Systematic review of the renal protective effect of Astragalus membranaceus (root) on diabetic nephropathy in animal models. J Ethnopharmacol. 126:189–196. 2009. View Article : Google Scholar : PubMed/NCBI
32	Chen X, Cao A, Wang L, Yin P, Zhang X and Peng W: Prevention and treatment of diabetic nephropathy using traditional Chinese medicine. J Integr Nephrol Androl. 1:53–57. 2014. View Article : Google Scholar
33	Wang H, Li J, Yu L, Zhao Y and Ding W: Antifibrotic effect of the Chinese herbs, Astragalus mongholicus and Angelica sinensis, in a rat model of chronic puromycin aminonucleoside nephrosis. Life Sci. 74:1645–1658. 2004. View Article : Google Scholar : PubMed/NCBI
34	Shimomura H and Spiro RG: Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes. Decreased levels of heparan sulfate proteoglycan and laminin. Diabetes. 36:374–381. 1987. View Article : Google Scholar : PubMed/NCBI
35	Rops AL, van der Vlag J, Lensen JF, Wijnhoven TJ, van den Heuvel LP, van Kuppevelt TH and Berden JH: Heparan sulfate proteoglycans in glomerular inflammation. Kidney Int. 65:768–785. 2004. View Article : Google Scholar : PubMed/NCBI
36	van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, Vlodavsky I, van der Vlag J and Berden JH: Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 70:2100–2108. 2006. View Article : Google Scholar : PubMed/NCBI
37	Shafat I, Agbaria A, Boaz M, Schwartz D, Baruch R, Nakash R, Ilan N, Vlodavsky I and Weinstein T: Elevated urine heparanase levels are associated with proteinuria and decreased renal allograft function. PLoS One. 7:e440762012. View Article : Google Scholar : PubMed/NCBI
38	Maxhimer JB, Somenek M, Rao G, Pesce CE, Baldwin D Jr, Gattuso P, Schwartz MM, Lewis EJ, Prinz RA and Xu X: Heparanase-1 gene expression and regulation by high glucose in renal epithelial cells: A potential role in the pathogenesis of proteinuria in diabetic patients. Diabetes. 54:2172–2178. 2005. View Article : Google Scholar : PubMed/NCBI
39	van den Hoven MJ, Rops AL, Bakker MA, Aten J, Rutjes N, Roestenberg P, Goldschmeding R, Zcharia E, Vlodavsky I, van der Vlag J and Berden JH: Increased expression of heparanase in overt diabetic nephropathy. Kidney Int. 70:2100–2108. 2006. View Article : Google Scholar : PubMed/NCBI
40	Kramer A, van den Hoven M, Rops A, Wijnhoven T, van den Heuvel L, Lensen J, van Kuppevelt T, van Goor H, van der Vlag J, Navis G and Berden JH: Induction of glomerular heparanase expression in rats with adriamycin nephropathy is regulated by reactive oxygen species and the renin-angiotensin system. J Am Soc Nephrol. 17:2513–2520. 2006. View Article : Google Scholar : PubMed/NCBI
41	Tan AL, Forbes JM and Cooper ME: AGE, RAGE and ROS in diabetic nephropathy. Semin Nephrol. 27:130–143. 2007. View Article : Google Scholar : PubMed/NCBI